Non-invasive Multi-modal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn’s Disease.

Non-invasive Multi-modal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Apr 14;: Authors: Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S Abstract Fibrotic strictures occur in 30% of patients with Crohn’s disease (CD). However, there are no therapeutic agents that prevent or reverse fibrotic strictures. Strictures are treated by endoscopic dilatation procedures and surgical procedures, but there are high rates of recurrence. Two anti-fibrotic agents (nintedanib and pirfenidone) were recently approved for the treatment of idiopathic pulmonary fibrosis and inhibitors…

Read More

Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review.

Related Articles Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut. 2019 Apr 03;: Authors: Bettenworth D, Bokemeyer A, Baker M, Mao R, Parker CE, Nguyen T, Ma C, Panés J, Rimola J, Fletcher JG, Jairath V, Feagan BG, Rieder F, Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Abstract Patients with Crohn’s disease commonly develop ileal and less commonly colonic strictures, containing various degrees of inflammation and fibrosis. While predominantly inflammatory strictures may benefit from a medical anti-inflammatory treatment, predominantly fibrotic strictures currently…

Read More

Efficacy of Endoscopic Dilation of gastroduodenal Crohn’s disease strictures: A Systematic Review and Meta-analysis of Individual Patient Data.

Related Articles Efficacy of Endoscopic Dilation of gastroduodenal Crohn’s disease strictures: A Systematic Review and Meta-analysis of Individual Patient Data. Clin Gastroenterol Hepatol. 2018 Nov 29;: Authors: Bettenworth D, Mücke MM, Lopez R, Singh A, Zhu W, Guo F, Matsui T, James TW, Herfarth H, Goetz M, Mao R, Kurada S, Hampe J, Matthes K, Karstensen JG, Valli PV, Duijvestein M, D’Haens G, Jairath V, Qiu TB, Ding NS, Rogler G, Rieder F Abstract BACKGROUND & AIMS: Little is know about the effects of endoscopic balloon dilation (EBD) for strictures…

Read More

The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn’s Disease.

The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn’s Disease. Inflamm Bowel Dis. 2018 Oct 19;: Authors: Mao R, Kurada S, Gordon IO, Baker ME, Gandhi N, McDonald C, Calvin Coffey J, Rieder F Abstract Adipose tissue is present in close proximity to various organs in the human body. One prominent example is fat contained in the mesentery that is contiguous with all abdominal digestive organs including the intestine. Despite the fact that mesenteric fat-wrapping around the inflamed gut (so called “creeping fat”) was described…

Read More

Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn’s Disease.

Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1682-1683 Authors: Li JD, Xu XF, Xing H PMID: 30243356 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30243356?dopt=Abstract

Read More

Association Between Plasma Level of Collagen Type III alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn’s Disease.

Related Articles Association Between Plasma Level of Collagen Type III alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2018 Sep 10;: Authors: Ballengee CR, Stidham RW, Liu C, Kim MO, Prince J, Mondal K, Baldassano R, Dubinsky M, Markowitz J, Leleiko N, Hyams J, Denson L, Kugathasan S Abstract BACKGROUND & AIMS: There are few serum biomarkers to identify patients with Crohn’s disease (CD) who are at risk for stricture development. The extracellular matrix components, collagen type III alpha 1 chain (COL3A1)…

Read More

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease.

Related Articles An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V Abstract BACKGROUND: Fibrotic stricture is a common complication of Crohn’s disease (CD) affecting approximately half of all patients. No specific…

Read More

Endoscopic management of Crohn’s strictures.

Related Articles Endoscopic management of Crohn’s strictures. World J Gastroenterol. 2018 May 07;24(17):1859-1867 Authors: Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G Abstract Symptomatic intestinal strictures develop in more than one third of patients with Crohn’s disease (CD) within 10 years of disease onset. Strictures can be inflammatory, fibrotic or mixed and result in a significant decline in quality of life, frequently requiring surgery for palliation of symptoms. Patients under the age of 40 with perianal disease are more likely to suffer from disabling ileocolonic disease thus…

Read More
<< Go Back